Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 1 | 57.4% | +36.7% |
| FAN, LYNN Y | 1 | 47.6% | +48.7% |
| SIFFORD, JEFFREY MARK | 1 | 55.7% | +32.1% |
| CONSTANTINE, CHARLES Z | 1 | 59.0% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906631 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16368330 | METHODS AND PHARMACEUTICALS FOR TREATMENT OF VIRAL INFECTIONS OF THE EYE | CONSTANTINE, CHARLES Z | 28d |
| 18547164 | PHARMACEUTICAL COMPOSITIONS COMPRISING RANPIRNASE | SWIFT, CANDICE LEE | — |
| 17996577 | TREATMENT OF VIRAL CONJUNCTIVITIS | FAN, LYNN Y | — |
| 17906631 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1657 | 2 |
| 1759 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547164 | PHARMACEUTICAL COMPOSITIONS COMPRISING RANPIRNASE | SWIFT, CANDICE LEE | 1657 | §102§103§112DPOther | Non-Final OA | — | Pending | Aug 21, 2023 |
| 17996577 | TREATMENT OF VIRAL CONJUNCTIVITIS | FAN, LYNN Y | 1759 | §103 | Final Rejection | — | Pending | Oct 19, 2022 |
| 17906631 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | SIFFORD, JEFFREY MARK | 1671 | §101§103§112Other | Non-Final OA | — | Pending | Sep 19, 2022 |
| 16368330 | METHODS AND PHARMACEUTICALS FOR TREATMENT OF VIRAL INFECTIONS OF THE EYE | CONSTANTINE, CHARLES Z | 1657 | §103 | Final Rejection | 28d | Pending | Mar 28, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial